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Tolerance is a particularly well-researched adaptive re-
sponse to opioids, and is almost exclusively associated
with analgesia. Operationally, it is defined as a loss ofTolerance, one of several behavioral adaptations to
analgesic efficacy following continued use of opioidprolonged opioid treatment, has long been explained
drugs. Although easy to describe, the phenomenon isby desensitization of opioid receptor signaling and
complex. Exploring early events of opioid tolerance, bio-loss of surface receptors. However, recent evidence
chemists and electrophysiologists found modificationspresents an alternative hypothesis, suggesting that
of opioid receptor-associated ion channels and secondreceptor internalization could in fact reduce tolerance
messenger pathways in several brain areas (Williams etin vivo.
al., 2001). Pharmacological agents and molecular biol-
ogy approaches were used in vivo, and data suggestedThe Holy Grail
that several protein kinases, including PKA, PKC, andThe behavioral adaptations to prolonged use of opioid
CaMKII, glutamate receptors, cytoskeleton proteins, ordrugs such as heroin and morphine include tolerance,
neurotrophic factors are involved (Nestler, 1996). Sev-defined as a reduced sensitivity to the drug effects and
eral knockout animals show alteration of morphine toler-generally referring to attenuation of analgesic efficacy,
ance, revealing that multiple genes may influence thisand dependence revealed by drug craving and the phys-
adaptation at the genetic level. To further complicateiological manifestations of drug withdrawal. Further-
the picture, Siegel and colleagues, as early as in themore, in rodents, repeated morphine administration can
seventies, demonstrated that animals made tolerant toresult in sensitization of locomotor response, whereby
morphine in one environment were not tolerant whenprevious drug exposure enhances opioid-induced in-
tested in another (Siegel, 1976), stressing the contextcreases in locomotion, a phenomenon generally associ-
as an important variable in determining tolerance. Un-ated with psychostimulants such as cocaine. Adaptive
derstanding the molecular basis for this elaborate re-responses to repeated opioid administration are impor-
sponse to chronic opioids certainly is a challenge. Attant considerations in the clinical arena and lead physi-
present, it is clear that all the long-term changes origi-cians to hesitate prescribing opioid drugs for the treat-
nate from mu receptor activation, but what comes nextment of pain. The “holy grail” of opioid research has
has remained within the black box. What are the molecu-long been to develop drugs, or drug administration strat-
lar events associated with mu receptor activation thategies, that result in effective analgesia without the detri-
initiate the development of tolerance?mental adaptive responses. The recent work in the opi-
The Classical Hypothesis
oid field, including the article by He et al. published in
To address this issue, cellular models of tolerance have
Cell (2002) provides evidence for an emerging hypothe-
been developed. Illustrated in Figure 1A is the classical
sis to understand and optimize the analgesic effects of view of cellular tolerance that emerged from earlier stud-
long-term opioid treatments. ies. In analogy to other G protein-coupled receptors
Multiple Opioid Receptors (Ferguson, 2001), the prevailing hypothesis was that
Several distinct circuits of the central nervous system continued agonist treatment could induce several dis-
likely control the different adaptations to chronic opi- tinct events, which all contribute to limit agonist signal-
oids, but whether each adaptation is underscored by the ing. First, phosphorylation and arrestin binding results
same cellular and molecular mechanisms has remained in uncoupling of the receptor from G proteins, which
controversial. In the seventies and eighties, pharmaco- reduces agonist efficacy. Second, receptor internaliza-
logical approaches identified multiple opioid receptors tion and degradation would result in fewer available
and much effort was aimed at developing drugs which receptors at the cell surface. Together, these events
target receptor sites that elude addiction and tolerance. would cause signaling desensitization and could intu-
Although the pharmacology predicted a plethora of opi- itively explain cellular tolerance to opiates.
oid receptor genes, cloning of the opioid receptors in Besides adaptations at the receptor level, the cellular
the early nineties identified only three, the mu, delta, models of tolerance also revealed profound alterations
and kappa genes (for review see Kieffer, 1995). Opioid of signaling. Although acute opioid agonists typically
receptors were shown to belong to the extensive family induce a decrease in cAMP levels, prolonged treatment
of seven transmembrane G protein-coupled receptors. was found to trigger robust upregulation of cyclase ac-
Knockout of the mu receptor gene abolished the analge- tivity (cyclase supersensitivity). This later adaptive re-
sponse opposes opioid activity and possibly contributes
to the apparent lower opioid agonist efficacy. Cyclase3 Correspondance: briki@igbmc.u-strasbg.fr
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Figure 1. The Evolving Hypotheses for Mor-
phine Tolerance
(A) Early studies propose that a decrease of
functional mu receptors is responsible for tol-
erance. (B) In the presence of “internalizing”
opioids, exemplified by DAMGO, signaling is
rapidly terminated then rapidly possible
again. Downstream adaptations, therefore,
are limited by receptor recycling. In contrast,
a “non-internalizing” opioid such as morphine
is unable to efficiently trigger receptor se-
questration, and tolerance develops from
sustained signaling. The empty mu receptor
is shown as a circle, while DAMGO- and mor-
phine-bound receptors are schematized as a
square and a diamond, respectively. Events
unlikely to occur are indicated in gray. (C) In
the He et al. hypothesis (2002), sub-threshold
concentrations of DAMGO drag morphine-
bound receptors into the cell via receptor
oligomerization, and this would limit mor-
phine tolerance.
supersensitivity is considered one of the cellular adapta- in mu receptor-transfected cells suggested that mu re-
ceptor signaling differed among agonists, and was dis-tions that may underlie neuronal hyperactivity observed
during opioid withdrawal (Nestler, 1996), but its role in sociable from opioid-induced receptor internalization
(reviewed in Evans et al., 2000). More generally, thecellular desensitization and in vivo tolerance has yet to
be determined. notion emerged that several distinct active conforma-
tions of the mu receptor could form the basis for ligand-The Morphine Paradox
Recent observations have led scientists to revise the dependent cellular responses, and opened the possibil-
ity for a wide spectrum of activities from a single recep-classical view of tolerance. A key finding was that mor-
phine does not promote efficient receptor internalization tor protein. In short, the ligand-receptor complex, rather
than the receptor itself, was the key. Last, studies on the(Arden et al., 1995; Keith et al., 1996). How then, could
morphine tolerance arise from a loss of available recep- fate of internalized G protein-coupled receptors showed
that sequestration did not necessarily commit receptorstors? In addition, morphine also proved to be a poor
inducer of mu receptor phosphorylation and desensiti- to degradation, but led, at least in part, to receptor
dephosphorylation and recycling to the cell surface (Lef-zation (Whistler et al., 1999; Yu et al., 1997). How could
the prototypic opiate be unable to trigger main regula- kowitz et al., 1998). The internalization process therefore
was also a mechanism to reactivate desensitized recep-tory cellular adaptations and be so highly efficient in
inducing tolerance in vivo? A next step was to extend tors and receptor trafficking outward was as important
as inward.those studies to other mu agonists and further data
showed an amazing diversity of cellular responses. An Alternative Hypothesis
A very different explanation for morphine tolerance canOther opioids such as the mu-selective peptide DAMGO
and the alkaloid fentanyl were efficient at cellular desen- be contemplated from this body of observations (Figure
1B). In this hypothesis, adaptations are agonist depen-sitization, contrary to morphine (Kovoor et al., 1998 and
references within). Many opioids, including endogenous dent. An “internalizing” agonist triggers both receptor
signaling and receptor sequestration/recycling with highopioids, DAMGO, methadone, and etorphine, induced
the classically expected receptor sequestration, while efficacy. Receptor signaling is rapidly desensitized as
in the classical view (Figure 1A), but also rapidly reset, atmorphine, as well as some other low efficacy opioid
drugs, did not. Further comparison of agonist activities least partially. The opioid peptide DAMGO or the alkaloid
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etorphine typically represent such “internalizing” ago- proposed mechanism (see Figure 1C). Taking the results
step by step, a first important experiment shows thatnists. In contrast, morphine signals to downstream ef-
fectors—although with lower efficacy—but is unable to DAMGO (the high efficacy, internalizing opioid), adminis-
tered at concentrations below the threshold for inducinginduce extensive cellular desensitization. Receptors re-
main active on the cell surface and morphine signaling internalization, can induce internalization of mu recep-
tors in the presence of morphine (the partial agonist,is maintained. Compensatory mechanisms, including
cyclase supersensitivity, develop within mu receptor- unable to induce internalization). This dragging of recep-
tors to internal compartments is attributed to oligomer-bearing cells to counteract this sustained signaling, and
those changes in turn influence associated neurons ization of mu receptors. The hypothesis then is that the
few DAMGO-occupied receptors, which do not evidentlyspreading adaptations throughout brain circuits. Thus,
instead of relating opioid tolerance directly to desensiti- internalize due to their low number, are able to pull the
vast majority of morphine-bound receptors inside thezation of receptor signaling, it is proposed that the lack
of receptor desensitization after morphine treatment re- cell, leading to detectable receptor internalization. Sup-
port for the concept of receptor dragging is providedsults in abnormally prolonged signaling which exacer-
bates tolerance (Borgland, 2001). The fact that mu ago- by recent data, principally from the Devi lab, showing
that opioid receptors can form homo- or heterodimers,nists all display distinct signaling and internalizing
efficacies has led Whistler and colleagues to propose that a phenomenon which alters their pharmacological and
trafficking properties (Jordan and Devi, 1999). Severalmeasurement of relative agonist signaling versus endo-
cytosis (RAVE) could be predictive of tolerance liability experiments in He’s report, not detailed here, confirm
the possibility of mu receptor oligomerization. A next(Whistler et al., 1999). The relatively good ability of mor-
phine to signal in conjunction with its poor ability to inter- exciting finding in the He et al. paper is that submaximal
concentrations of DAMGO are shown to inhibit the cy-nalize receptors would confer a high RAVE value to the
compound and be indicative of a high potential to induce clase supersensitivity induced by morphine. This is at
first glance not an intuitive finding, and the most plausi-tolerance. For DAMGO or etorphine, high signaling effi-
cacy combined with high internalization potency would ble explanation is that traces of DAMGO promote inter-
nalization of the morphine-bound receptors, inducing alead to a low RAVE value, hence low tolerance potential.
In brief, strong internalization would limit tolerance while loss of surface receptors and a diminution in morphine
signaling which is responsible for inducing supersensi-sustained signaling—even if less efficient—would favor
the development of adaptations. tivity. In short, DAMGO-induced receptor internalization
provides a brake for morphine signaling via receptorIn Vivo Correlates?
This extremely appealing hypothesis was mainly based oligomerization, as schematized on Figure 1C. These
are data from transfected cells. To test the hypothesison studies in transfected cells. Do in vivo data support
this? In vivo studies correlating agonist efficacy versus that internalization could influence morphine tolerance
in vivo, He et al. used a rat model with chronically im-tolerance liability have been rare, as discussed in the
paper by He et al. (2002). A study by Young and Walker planted intrathecal catheter to administer morphine con-
tinuously and DAMGO acutely. The key finding is thatillustrates the complexity of in vivo approaches (Walker
and Young, 2001). This study investigated tolerance and analgesia following continuous administration of mor-
phine is markedly enhanced when a sub-analgesic con-cross-tolerance for three very different opioids: mor-
phine, the partial mu agonist that does not induce rapid centration of DAMGO is co-administered. In the same
morphine- or morphine/DAMGO-treated animals, He etinternalization, etonitazene, a potent and highly effica-
cious mu opioid that induces rapid internalization, and al. investigate mu receptor internalization in the rat spi-
nal cord. Consistent with the in vitro data, as well asbuprenorphine, a low efficacy nonselective agonist
which induces an increase in surface mu receptors. This the lack of analgesia, they find that the sub-threshold
concentration of DAMGO is too low to trigger mu recep-paper and studies referenced within, conclude that the
ability to develop tolerance is inversely related to effi- tor internalization by itself. In contrast, this sub-effective
dose facilitates morphine endocytosis, which is other-cacy, and therefore indirectly supports the model (Figure
1B). However, the data do not give clear-cut relation- wise not observed in the spinal cord. The interpretation
is that by internalizing morphine-occupied receptors,ships; for example, the analgesic actions of etorphine
are made tolerant by prior etonitazine treatment, but not DAMGO is limiting tolerance.
The Implicationsby morphine treatment. The lack of predictable toler-
ance relationships underlines a reality that every opioid The underlying concepts for morphine tolerance are re-
fined by He’s report. The study suggests that a mor-drug has a unique combination of properties with regard
to duration of action, metabolism, receptor selectivity, phine/DAMGO cocktail would combine benefits from
the two drugs: the well-known strong analgesic activityreceptor association and dissociation rates, efficacy for
signaling, lipophilicity, and ability to influence receptor of acute morphine, with the regulatory properties of
DAMGO (short acting signaling and receptor resensitiza-trafficking. It is probable that all these parameters influ-
ence the development of tolerance in vivo. tion). Figure 1C, however, depicts the model of com-
bined drugs on the regulation of the mu receptor signal-Internalization And Tolerance
The possibility of a true link between mu receptor inter- ing, but does not reflect the complexity of in vivo
experimentation. Further studies will be necessary tonalization at the cellular level, and tolerance in vivo finally
found support in the work reported by He et al. (2002). elucidate the clinical usefulness of this observation. For
example, in the morphine tolerant state, it will be criticalAs depicted in Figure 1B, their data implicate a role of
internalization as providing protection against tolerance, to determine the time course of the ability for DAMGO
to enhance morphine analgesia, i.e., how long does thebut their report adds another level of complexity to the
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apparent braking of tolerance last? Proponents of the Either way, the diversity of signaling between opioid
classical desensitization hypothesis would predict that agonists provides a vast potential for future research
there would be even greater tolerance to morphine ob- that will ultimately determine whether or not the simplifi-
served after the DAMGO has internalized the mu recep- cation of opioid tolerance implicated by the RAVE hy-
tors and been metabolized. Studies must also assess pothesis holds true.
whether the in vivo results could be explained by sub- Conclusion
threshold concentrations of DAMGO acting synergisti- So where do we stand in our quest for the holy grail of
cally with morphine to promote analgesia. This may oc- opioid research and the understanding of tolerance?
cur, for example, via internalization-enhanced signaling First, we must accept tolerance to analgesia as a com-
or due to lower pain thresholds in morphine-infused plex behavioral response. Second, we have to anticipate
animals compared to naive controls (see Gutstein, 1996). that every opioid drug will be unique in many properties
Thus, one possible scenario is that DAMGO administra- that undoubtedly contribute to the timing and extent
tion transiently masks, rather than prevents, morphine of tolerance. With regard to internalization as a key to
tolerance. Finally, preclinical data have shown that toler- tolerance, the He et al. paper provides some intriguing
ance develops differently following intermittent or con- data. However, prior to clinical consideration, more in-
tinuous opioid administration (Duttaroy and Yoburn, depth studies will be necessary to address the many
1995) and data from true co-administration experiments facets of opioid tolerance that have emerged during the
may be of great interest to further explore possible bene- past few decades of research.
fits from the association of mu opioids with different
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Based on this hypothesis, the potential for diversity of
opioid receptor pharmacology becomes enormous.
Combined with the emerging evidence for ligand-
directed signaling, different agonists may selectively ac-
tivate specific heteromeric complexes, which contain
their own unique entourage of signaling machinery. Al-
ternatively, given a specific heteromeric complex, differ-
ent agonists may have different abilities to activate spe-
cific signaling pathways linked to the same receptor
complex, i.e., by selective release of  or / subunits.
